tiprankstipranks
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (SFOSF)
OTHER OTC:SFOSF

Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Price & Analysis

Compare
21 Followers

SFOSF Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

3.62%94.37%
Insiders
― Other Institutional Investors
94.37% Public Companies and
Individual Investors

SFOSF FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was $1.23 and its highest was $2.24 in the past 12 months.
    What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
    Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is $8.24B.
      When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
      Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Mar 25, 2025 which is yesterday.
        How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
        Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Mar 25, 2025. The company reported $0.035 earnings per share for the quarter, the consensus estimate of $0.035 by $0.
          Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
          According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
            Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of $0.039 which represents an annual dividend yield of 2.02%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
              What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
              Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.04.
                How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
                Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
                  What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
                  Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of $0.035 in its last earnings report, expectations of $0.035. Following the earnings report the stock price went up 1.053%.
                    Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
                    Currently, no hedge funds are holding shares in SFOSF
                    ---

                    Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

                    Company Description

                    Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

                    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
                    ---

                    SFOSF Stock 12 Month Forecast

                    Average Price Target

                    $1.83
                    ▼(-3.68% Downside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.826475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.826475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.83</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.83,1.8297288461538461,1.8294576923076924,1.8291865384615384,1.8289153846153847,1.8286442307692308,1.828373076923077,1.828101923076923,1.8278307692307694,1.8275596153846154,1.8272884615384617,1.8270173076923077,1.826746153846154,{"y":1.826475,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.83,1.83,1.83,1.83,1.83,1.83,1.83,1.83,1.83,1.83,1.83,1.83,1.83,{"y":1.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.83,1.8297288461538461,1.8294576923076924,1.8291865384615384,1.8289153846153847,1.8286442307692308,1.828373076923077,1.828101923076923,1.8278307692307694,1.8275596153846154,1.8272884615384617,1.8270173076923077,1.826746153846154,{"y":1.826475,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.1,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.2,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.24,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.98,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.82,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.86,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.63,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.7,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.68,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.44,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.38,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.38,"date":1696118400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Sino Biopharmaceutical
                    CSPC Pharmaceutical Group
                    Livzon Pharmaceutical Group
                    China Resources Pharmaceutical Group Ltd.
                    Kingworld Medicines Group Ltd.

                    Best Analysts Covering SFOSF

                    1 Year
                    No data currently available
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis